

This is the final peer-reviewed accepted manuscript of:

Cunto M, Mariani E, Anicito Guido E, Ballotta G, Zambelli D. Clinical approach to prostatic diseases in the dog. Reprod Domest Anim. 2019 Jun;54(6):815-822.

The final published version is available online at: <https://doi.org/10.1111/rda.13437>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

1 **CLINICAL APPROACH TO PROSTATIC DISEASES IN THE DOG**

2 Running Title: Prostatic disorders in dogs

3 Marco Cunto, Elisa Mariani, Eleonora Anicito Guido*, Giulia Ballotta, Daniele Zambelli

4 Department of Veterinary Medical Sciences, Alma Mater Studiorum - University of Bologna,
5 Ozzano dell'Emilia (Bo), Italy.

6 *Corresponding Author: eleonora.anicito2@unibo.it

7 **Abstract**

8 In small animal practice, prostatic diseases are increasingly encountered. All dogs may experience
9 prostatic disease, but particular care should be addressed to breeding dogs, in which prostatic
10 affection may lead to decrease in semen quality and fertility. The most common prostatic disease is
11 the benign prostatic hyperplasia (BPH) followed by prostatitis, prostatic neoplasia and prostate
12 squamous metaplasia. These diseases do not have pathognomonic symptoms, therefore, making a
13 correct diagnosis may not be easy. An accurate clinical examination and a correct diagnostic protocol
14 are essential in order to begin the most appropriate treatment, and also to do a good prophylaxis where
15 it is possible.

16 BPH therapy is usually recommended when mild-severe signs are present or if symptoms disturb the
17 patient. New therapeutic approaches, both medical and surgical, allow to maintain fertility in most
18 animals with prostatic disorders. Prostate cancer is relatively infrequent. Elective therapy is the
19 surgical one, but it is considered palliative and can result in important post-operative complications.
20 The aim of these paper is to lay down the most appropriate diagnostic process describing the
21 aetiologies of prostatic disease, their symptoms, the right investigative tools and therapy.

22

23 Keywords: prostate, dog, prostatic diseases, diagnosis, therapy.

24

25 **INTRODUCTION**

26

1 Prostatic diseases are very common in male dogs and are the main pathologies affecting the
2 reproductive system; these animals are much more frequently presented for such reasons (Davidson,
3 2014). Benign prostatic hyperplasia is the most common benign neoplastic disease in both the aging
4 dog and man and therefore the dog has been increasingly used as an experimental animal model for
5 the study of this important human disease. Frequently the clinical approach to prostatic diseases is
6 not easy: these pathologies can occur concomitantly, can be asymptomatic and are often
7 underestimated because many of the major symptoms of prostatic diseases are non-specific. Systemic
8 signs, lower urinary signs, abnormalities of defecation and locomotion disorders are symptoms that
9 occur in prostatic diseases, but are also observed in low urinary tract, intestinal tract and orthopedic
10 pathologies. For a correct management it is essential to know the history and perform a correct
11 physical examination. Development in the diagnostic and therapeutic approaches over the last decade
12 has permitted to maintain fertility in many dogs with prostatic pathologies. (Read and Bryden, 1995;
13 Krawiec and Heflink, 1992).

14

15 *Anatomy and physiology*

16 The prostate gland is the only accessory sex gland in the male dog and provides, with its secretions,
17 the transport of sperm outwards and an ideal environment for the development and survival of sperm
18 (Branam et al. 1984). It is a bilobed and mobile organ that encircles the urethra and the neck of the
19 urinary bladder. Its anatomic topography is variable and depends on the age and the bladder
20 distension, while only its craniodorsal and cranioventral sides are covered by peritoneum. Prominent
21 medial septum and other minor septa rich of connective tissue and smooth muscular fibers originate
22 from the external thick fibromuscular capsule and split the organ in two major lobes and then in
23 lobules. The glands are tubuloalveolar with a tall columnar secretive epithelium and sporadic basal
24 cells. The openings of prostatic glandular ducts are located in urethra near deferent ducts around the
25 colliculus seminalis.

1 Prostatic artery from the pudendal internal artery and hypogastric nerve provide the vascular and
2 nervous supply (Evans et al, 2013). Theoretically, the canine prostate passes from three stages of
3 development that usually are not clearly distinguishable. O'Shea (1962) divided prostatic
4 development into three phases: the first, of normal growth, in the young dog; the second, of
5 hyperplasia, during the middle and adult age; the last of senile involution (O'Shea, 1962).
6 The development and maintenance of prostatic secretory activity are guaranteed by hormone
7 production. Testosterone penetrates prostate cells by diffusion and is metabolized into other steroids
8 by enzymes. More than 95% of the testosterone is converted into DHT by 5 α -reductase in the prostate.
9 DHT binds and activates cytoplasmic receptors for androgens with greater affinity than testosterone.
10 Another hormone involved in prostate development is 17 β -estradiol, which is synthesized by
11 aromatase. This estrogen works in synergy with androgens (Frick and Aulitzky, 1991).
12 More recent studies show that 17 β -estradiol increases the expression of nuclear receptors for DHT,
13 thus increasing the sensitivity of the prostate to androgens (Gobello and Corrada, 2002).
14 Moreover, canine prostate-specific arginine esterase (CPSE), the major secretory product of the
15 canine prostate, is the most abundant protein in the dog's prostate fluid and represents more than 90%
16 of the seminal plasma proteins in this species. It could be a useful diagnostic marker to identify
17 prostatic disorders (Chapdelaine et al., 1984).

18

19 ***Prostatic diseases***

20 The prostatic pathologies should be classified into endocrine, inflammatory (septic and non-septic),
21 neoplastic and traumatic (Ballotta and Cunto, 2018). Benign prostatic hyperplasia and squamous
22 metaplasia belong to the first category while acute or chronic prostatitis and prostatic abscess belong
23 to the second one. Cysts frequently occur secondary to other prostatic diseases. It is important to
24 remember that more prostatic diseases can be present simultaneously (Barsanti and Finco, 1986).

25

26 ***Benign prostatic hyperplasia***

BPH is a benign neoplastic disease that occurs only in man, dog, chimpanzee and, despite some differences, the natural course of BPH is similar in these species. BPH is the most common prostatic disease diagnosed in the dog and affects about 80% of intact male dogs over 5 years old (Sirinarumitr et al., 2001) and more than 95% of intact male dogs over 9 years old (Gobello and Corrada, 2002). Large breeds such as Doberman, German Shepherd, Rhodesian Ridgeback and Labrador Retriever appear to be predisposed to BPH (Wolf et al., 2012; Polisca et al., 2016; Das et al., 2017;). Several theories have been proposed to explain the etiology but only three facts have proven to be implied in both species:

1. the incidence of BPH increases with advanced age;
2. the presence of functioning testes is required;
3. dihydrotestosterone (DHT), the active metabolite of testosterone, is more concentrated in hyperplastic prostatic tissue compared to normal tissue.

With aging, when the estrogen/testosterone ratio increases, the prostate becomes more responsive to androgen action. The key role in this pathology is probably played by a metabolic shift that promotes the production of DHT due to increase of 5 α -reductase activity (Brendler et al., 1983; Gobello and Corrada, 2002). Intraparenchymal cysts are frequently associated to BPH and are formed when hyperplastic glandular ducts become obstructed causing accumulation of prostatic fluid (Barsanti and Finco, 1986) or urine when a communication with the urethra is present (Bokemeyer et al., 2011). Frequently the dogs with BPH are asymptomatic, but when clinical signs are present, the most common is a serous to sanguineous urethral discharge, produced by hyperplastic tissue with increased vascularity. Sometimes sanguineous discharge enters in urinary bladder and so hematuria may be present. Rectal tenesmus, constipation, dischezia and rarely dysuria, strangury and incontinence can occur because of an enlarged prostate or large cysts associated with BPH. Caudal abdominal pain and infertility can be observed, while systemic signs are rarely reported (Krawiec and Heflink, 1992; Read and Bryden, 1995).

1 A presumptive diagnosis can be made by history, physical examination, laboratory findings and
2 prostatic imaging. Biopsy permits a definitive diagnosis but is rarely recommended (Smith, 2008).
3 Enlargement of the prostate can be detected by rectal palpation during physical examination. The
4 prostate is usually not painful, symmetrically enlarged and with normal consistency. Sometimes the
5 organ is not symmetric because of large intraparenchymal cysts or the cobblestone-like appearance
6 of its surface (Lopate, 2013). Hematologic findings and urinalysis are usually normal even if
7 hematuria may be present (Das et al., 2017) and the prostatic fraction of seminal plasma too is
8 frequently hemorrhagic. Aerobic and anaerobic cultures of seminal plasma and urine are negative
9 (Read and Bryden, 1995) while cytology and bacterial culture of prostate secretions may be useful to
10 exclude or to confirm the concomitance of multiple prostatic disorders, even if do not provide
11 definitive diagnosis of BPH (Greer, 2014). Samples can be obtained by ejaculation, prostatic
12 massage, fine needle aspiration or urethral brushing (Gobello et al., 2002; Lopate et al., 2013).
13 Radiographically it is possible to evaluate prostatic size and position. It is usually enlarged and
14 located in the abdomen. The colon is dorsally displaced and the urinary bladder cranially displaced
15 (Feeney et al., 1987). The normal prostate size should not exceed 70% of the distance between the
16 pubic cranial margin and the sacral promontory, measured in lateral projection; over this value the
17 prostate is enlarged (Atalan et al., 1999). On ultrasonography the prostate appears frequently enlarged
18 and symmetric, with homogeneous parenchyma or with nodular aspect. Nodules are poorly defined
19 and are isoechoic or slightly different from normal parenchyma echogenicity. Frequently one or more
20 cysts are present, which appear like intraparenchymal cavity with variable size and shape and with
21 well-defined margins (Nyland and Mattoon, 2015). Advanced ultrasound techniques, such as colour-
22 coded and pulsed Doppler sonography, contrast-enhanced ultrasound and elastography, can be used
23 for a more complete evaluation of the prostate gland (Günzel-Apel et al., 2001; Vignoli et al., 2011;
24 Feliciano et al., 2015). Doppler evaluation is a non-invasive diagnostic tool easily applicable in
25 clinical practice and, in dogs with BHP, shows a significant increase of blood flow velocity in
26 prostatic artery (Zelli et al., 2013). Although few studies on contrast-enhanced ultrasound are

1 published, this method, giving detailed information on the prostate gland vascularization, can be
2 useful in detecting early prostate disease, in differentiate between malignant and benign lesions and
3 in staging already diagnosed diseases (Vignoli et al., 2011; Bigliardi and Ferrari, 2011). Elastography
4 evaluates the presence of deformities and tissue stiffness and, despite the few experimental studies
5 about it, seems to be a useful diagnostic tool allowing to discriminate between a normal prostate and
6 a pathological one (Feliciano et al., 2015; Domoslawska et al., 2018).

7 Serum evaluation of CPSE, considered as the most representative marker of prostate secretion
8 activity, may be helpful for diagnosis because it increases in the course of BHP (Lévy et al., 2009;
9 Wolf et al., 2012; Lévy et al., 2014; Holst et al., 2017; Pinhero et al., 2017). The results obtained by
10 Holst et al. (2017) revealed that dogs with an increase of prostate volume higher than 2,5 times of
11 normal expected volume showed serum CPSE levels more than 90 ng/mL (Holst et al. 2017). The
12 serum evaluation of the CPSE seems to be a new frontier in clinical practice such as screening tests
13 for prostate disease prevention or as routine tests for possible follow-ups (Alonge et al., 2017; Lévy
14 et al. 2017).

15 It is important to remember that BPH evolution is individual and difficult to predict. The symptoms
16 can be graded according to their severity, frequency and duration thanks to a symptom index validated
17 for BPH (Zambelli et al., 2012). Considering this classification and that the clinical signs may be the
18 same during many years, we can choose the best therapy for the single case and, so, no therapy is
19 usually recommended when mild signs are present or if symptoms do not disturb the patient. In this
20 case the patient is monitored every 3 to 6 months, on the basis of an approach called “watchful
21 waiting” frequently used in human beings (McVary et al., 2011). Therefore, we have different
22 therapeutic options: “watchful waiting”, pharmacological treatment, surgical treatment (orchiectomy,
23 cysts omentalization) (Barsanti and Finco, 1986) and cysts alcoholization (Zambelli et al., 2003). To
24 choose the best treatment, after physical examination and tests, it is possible to divide symptomatic
25 subjects in animal with mild, moderate or severe symptoms. In the first case or if moderate symptoms
26 don’t affect dog and/or owner life, watchful waiting is the best treatment. In every other case, when

1 symptoms affect dog and/or owner life, pharmacological or surgical treatment should be
2 recommended (Zambelli et al., 2012). In particular situations, when BPH is associated with
3 incontinence caused by bladder hyperdistention, severe dyschezia, presence of perineal hernias,
4 severe recurrent hematuria or urethral discharge, presence of big retention cysts, dysuria/acute urinary
5 retention, castration is the treatment of choice following which prostatic volume decreases within 7-
6 14 days after surgery. The drugs more frequently used for the pharmacological treatment
7 recommended in literature are: 5 α -reductase inhibitors (such as Finasteride), antiandrogens (such as
8 Flutamide and Osaterone acetate), GnRH analogs (deslorelin acetate) and progestogens (Smith,
9 2008). Finasteride is the drug of choice when surgical treatment is not recommended or possible
10 (Sirinarumitr et al., 2001); it prevents the conversion of testosterone to DHT and, like Flutamide, has
11 not been demonstrated to reduce libido and sperm production. Several dosages of Finasteride are
12 reported in the literature (Sirinarumitr et al., 2001; Iguer-Ouada and Verstegen, 1997; Lange et al.,
13 2001) but the most effective protocol that allows the lowest possible doses involves the administration
14 of 1.25 mg Finasteride (regardless of the dog's size and the severity of the disease) PO every 24 hours
15 for 195 days. Osaterone acetate is an anti-androgen agent; the administration of 0,2-0,5 mg/kg/day
16 PO for 7 days leads to a significant decrease in prostate volume, already evident at the end of the
17 treatment (Tsutsui et al., 2001). GnRH agonists have an action similar to endogenous GnRH. The
18 mechanism of action involves the constant release of the active ingredient from the implant that
19 overlaps the physiological one, leading to a supersaturation and down-regulation of the pituitary
20 receptors. The consequent decrease in FSH and LH leads to a drastic reduction of testosterone
21 synthesis (up to 90%) and, in the case of deslorelin acetate (4.7 mg implants), causes an evident
22 decrease in prostate volume (> 50% after 6 weeks) (Trigg et al., 2001). Progestogens (megestrol
23 acetate and medroxyprogesterone acetate) can be used but are not recommended because of the
24 several side effects (Smith, 2008). The employ of an anti-estrogenic compound, tamoxifen citrate, is
25 also reported in the literature; it gives a competitive block on estrogen receptors with a mixed agonist-
26 antagonist mechanism (Corrada et al., 2004). Moreover, some authors suggest the use of plants extract

to treat BPH (Odenthal, 1996), while others demonstrated the efficacy of pulsed electromagnetic field therapy on BHP in dogs with no apparent side effects (Leoci et al., 2014). When large cysts are present, the surgical treatments proposed in literature are: drainage, resection of the cyst with or without drainage placement, omentalization, marsupialization and partial or total prostatectomy (Smith, 2008). Among these, omentalization is the authors' preferred technique, also used to treat prostatic abscesses and described in the relevant chapter. A less invasive technique, not requiring surgery, consists of ultrasound-assisted cysts drainage and alcoholization. However, this medical procedure is not as effective on cysts as it is on abscesses, probably due to the different nature of the cyst's inner surface which seems to resist the alcohol's effect (Zambelli et al., 2003).

Acute and chronic prostatitis and prostatic abscesses

Acute prostatitis (AP) and chronic prostatitis (CP) are defined as an inflammation of the prostate gland. Septic prostatitis is the most common type of prostatic inflammatory disease, even if non-septic prostatitis is possible; sometimes chronic non-septic prostatitis is associated with BPH (Nizanski et al., 2014). In healthy dogs there are some non-specific defense mechanisms to reduce the risk of infections such as urinary flow during micturition, urethral pressure, local production of IgA and prostatic production of antibacterial factor (Shimizu et al., 1995). Conditions that alter these mechanisms or alterations of prostatic tissue such as BPH, squamous metaplasia and neoplasia can predispose to prostatic infections (Smith, 2008). Only one-third of prostatitis is caused by a single bacterial, the other two-third show a mixed growth of several infectious agents or are non-septic (Lévy et al., 2006). The most common responsible pathogens are aerobic organisms such as *E. coli*, *Staphylococcus sp.*, *Streptococcus sp.*, *Proteus sp.*, *Pseudomonas spp.*, *Brucella canis*, *Klebsiella sp.*; other reported pathogens are anaerobic organisms and *Distemper virus* while fungal conditions such as blastomycosis and cryptococcosis are infrequent in the dog (Barsanti and Finco, 1986; Krawiec and Heflink, 1992). Infections are often caused by bacteria ascending the urethra but local dissemination from urogenital organs or hematogenous spread is possible (Barsanti and Finco, 1986).

1 Sometimes prostatitis may develop into prostatic abscesses (PA). The symptoms vary with the
2 progression of the disease and from acute to chronic prostatitis to prostatic abscess. Dogs with AP
3 frequently present fever, anorexia, lethargy, caudal abdominal pain, constant or intermittent urethral
4 discharge. CP can be present without evident signs and is often associated to recurrent urinary tract
5 infection; sometimes anorexia, lethargy, urethral discharge and poor semen quality are present.
6 Symptoms related to PA vary from signs similar to AP to signs of peritonitis or septic shock if abscess
7 rupture occurs. If present, urethral discharge is hematic or purulent (Wallace, 2001).

8 Presumptive diagnosis is based on history, physical examination, laboratory findings, urine culture
9 and prostatic imaging. This diagnosis can be confirmed with prostatic fluid culture. Prostatic fluid
10 can be obtained by ejaculation, even if sometimes this is not possible because it is painful, or by
11 prostatic massage (Johnston et al., 2000). On physical examination for AP and PA prostate can be
12 painful when the organ is palpated or during the defecation. Prostatic size can be increased and shape
13 changed if underlying prostatic diseases or PA are present. Usually the prostatic consistency is fibrous
14 for CP while in course of AP and PA the prostate may present an increased firmness and fluctuant
15 areas may be palpated in the case of PA. The hemogram is normal for CP, a neutrophilic leukocytosis
16 with or without left shift is present during AP and PA and elevation of alkaline phosphatase is
17 frequently reported in PA. Pyuria, hematuria and bacteriuria are often observed in PA (Kutzler and
18 Yeager, 2005; Smith, 2008). Cytology from prostatic fluid or tissue is useful for diagnosis. In 80%
19 of case there is a correlation between prostatic fluid cytology and histologic evidence of inflammation
20 (Barsanti et al., 1983). Samples for cytology can be obtained by prostatic massage or in some cases
21 by ejaculation. A fine-needle aspiration and ultrasound-guided biopsy are reliable techniques too and
22 successful diagnosis has been reported in 70% of case, but these techniques must be use with caution
23 because of the potential of creating a septic needle tract (Smith, 2008; Lévy et al., 2014). In particular
24 they are contraindicated in presence of prostatic abscessation (Smith, 2008). In smear of acute
25 prostatitis and prostatic abscess, we observe many granulocytes, red blood cells and bacteria; if
26 present, prostatic cells may be normal or damaged. Radiographically, prostatic abscess occurs

1 sometimes as a prostatic enlargement, with colon and urinary bladder respectively dorsally and
2 cranially displaced and, in some cases, mineralization is detected. In case of cystourethrography, if the
3 cavitory lesion communicates with the urethra, a reflux of contrast medium into the prostatic
4 parenchyma is observed (Feeney et al., 1987).

5 Ultrasonography is very useful for diagnosis: prostate is enlarged in size and asymmetric for PA while
6 the parenchyma appears focally or diffusely hypoechoic for AP and PA and hyperechoic for CP. The
7 tissues around the prostate are normal or hypoechoic for AP and PA and normal for CP. Abscesses
8 may be single or multiple, with size varying from small to large, globose or multiloculated shape,
9 hypoechoic or anechoic internal aspect and irregular internal surface.

10 Elective therapy for prostatitis is based on antibiotic administration for long period, about 4 to 6
11 weeks (Sirinarumitr, 2009) and, in case of PA, should be associated with other treatment described
12 in the relevant section. Once AP or PA are diagnosed a broad-spectrum antibiotic should be
13 administered but as soon as the antibiogram is available, if necessary, antibiotic therapy should be
14 modified. In dogs with AP or PA the blood-prostate barrier is damaged and so antibiotic can easily
15 pass into the parenchyma (Dorfman and Barsanti, 1995). Different is in dogs affected by CP, for
16 which antibiotic should be chosen between drugs with a good prostatic penetration, because blood-
17 prostate barrier is intact (Dorfman and Barsanti, 1995). Antibiotics that allow good penetration of the
18 prostate barrier are those with high lipid solubility, pKa allowing diffusion of the non-ionised form
19 of the drug across the lipid membrane and low protein binding, such as trimethoprim,
20 chloramphenicol, and the fluoroquinolones such as enrofloxacin, ciprofloxacin and marbofloxacin
21 (Dorfman and Barsanti, 1995; Sirinarumitr, 2009). In all cases of prostatitis, treatment for hormone
22 deprivation (finasteride, osaterone, deslorelin) should be useful to increase the success of the therapy,
23 especially when other conditions, as BPH, are present. In dogs affected by PA, antibiotic therapy
24 should be associated with techniques able to drain the purulent material, such as omentization
25 (White and Williams, 1995). This is the authors' preferred technique, recommended for abscesses or
26 cysts treatment. During surgery abscess' content is partially aspirated with a syringe in order to

1 decrease internal pressure. The abscess is opened, the pus removed by suction and internal septa
2 broken-down by digital exploration. After cleaning the cavity with iodine tincture and irrigation with
3 warm saline, the omentum is distended, inserted in the cavity in order to fill it and then sutured with
4 few anchorage stitches. Follow up includes ultrasonographic evaluation, where the omentum appears
5 hyperechoic in comparison with the prostatic parenchyma and it fills the whole cavity. An
6 omentalization with modified technique allows to better safeguard the integrity of the vasa deferentia
7 in breeding animals (Zambelli and Bralia, 2000).

9 *Squamous Metaplasia*

10 Squamous metaplasia (SM) of prostatic cells is a condition secondary to exogenous or more
11 frequently endogenous hyperestrogenism, frequently due to functional Sertoli-cell tumour. SM
12 predisposes the prostate to prostatitis and abscesses (Lévy et al., 2014).

13 The main clinical signs are correlated to hyperestrogenism: alopecia, hyperpigmentation,
14 gynecomastia, and signs of prostatitis. Other symptoms are non-regenerative anemia,
15 thrombocytopenia, granulocytosis or granulocytopenia. When Sertoli-cell tumour is present, it could
16 be palpated in one or both the testis, and sometimes the dog may also be cryptorchid (Lévy et al.,
17 2014).

18 Presumptive diagnosis of prostatic SM is based on history, physical examination, preputial cytology,
19 testicular and prostatic imaging and testicular histology or cytology. Hyperestrogenism induces
20 modifications in both prostatic and preputial cells: prostatic fine-needle aspiration usually permits to
21 obtain a sample rich in large cells with a small nucleus and granulocytes; preputial swab permits to
22 obtain many superficial cells with more than 30% of keratinization (Gobello and Corrada, 2002). On
23 ultrasonography the prostate aspect is similar to that reported for acute or chronic prostatitis and
24 frequently cysts are present. For a definitive diagnosis, prostatic biopsy or cytology are required
25 (Leeds, 1969).

Metaplasia is reversible after removal of source of estrogens: orchiectomy is the elective treatment in cases of Sertoli-cells tumors while interruption of estrogens administration is recommended when hyperestrogenism is exogenous (Lipowitz et al., 1973).

Prostatic Neoplasia (PN)

Prostatic neoplasia is a rare disease (incidence of 0,43%) both in intact and neutered dogs (Axiak and Bigio, 2012), with Shetland sheepdogs and Scottish terriers having an increased risk (Bryan et al., 2007). The mean age of diagnosis is 10 years. The lack of markers for prostatic cancer in dogs makes early diagnosis difficult and therefore the true incidence of prostate cancer may be higher than currently believed (Teske et al., 2002). A higher prevalence of PN is seen in castrated dogs; however, both castrated and intact animals develop this pathology at the same age. This aspect suggests that castration is not an initiator of cancer, but that it favours tumor progression (Teske et al., 2002; Bryan et al., 2007). PN is considered hormonally independent and tends to metastasize rapidly in about 70-80% of cases through external or internal iliac nodes to vertebral bodies and lungs or may invade urethra, urinary bladder, ureters, colon and pelvic musculature (Hall et al., 1976; Leroy and Northrup, 2009). Adenocarcinoma, transitional cell carcinoma and undifferentiated carcinoma are the most common prostatic neoplasia reported (Cornell et al., 2000; Teske et al., 2002; Smith, 2008; Leroy and Northrup, 2009).

The presenting history is similar to that of other prostatic diseases, but frequently the symptoms are related to increased prostatic size that induces rectal tenesmus, constipation as well as diarrhea, dyschezia, hematuria, dysuria and stranguria. Lameness, pain and paresis of the hind limb (caused by nerve compression and vertebral metastasis), weight loss and caudal abdominal pain are also reported (Leroy and Northrup, 2009; Axiak and Bigio, 2012; Lévy et al., 2014). Secondary infection is reported in 36% of affected dogs and can exacerbate lower urinary tract signs (Leroy and Northrup, 2009).

History, physical examination, laboratory findings and prostatic imaging can lead to a presumptive

1 diagnosis but definitive diagnosis requires the collection of neoplastic prostatic cells by prostatic fine
2 needle aspiration or biopsy (Axiak and Bigio, 2012). On transrectal examination the prostate is
3 usually painful, asymmetrically enlarged, and with increased firmness. Hematuria is frequently
4 present, non-regenerative anemia, leukocytosis (mature neutrophilia) and increase of the alkaline
5 phosphatase may be reported (Bell et al., 1991; Axiak and Bigio, 2012). As already mentioned, there
6 are not markers for PN as in humans, therefore a serum screening test is not useful as a screening tool
7 (Leroy and Northrup, 2009). Ultrasound is the first choice examination: typically, prostate appears
8 enlarged, asymmetric, with an irregular and poorly defined outline. Focal or diffuse, hyperechoic or
9 mixed lesions can be found throughout the parenchyma. Hyperechoic foci with acoustic shadowing
10 representing mineralization as well as cavitary, cyst-like lesions varying in size, shape, and number
11 may also be present. Extension of pathologic changes to the urethra or neck of the urinary bladder,
12 regional lymphnode enlargement, and disruption of the capsule are ominous ultrasound signs
13 indicating neoplasia. (Smith, 2008; Mattoon and Nyland, 2015). A recent study shows that
14 elastography can be a very helpful diagnostic tool to diagnose prostate neoplasia in dogs, so that some
15 authors recommend including it among the first additional surveys in routine prostate examination
16 (Domoslawska et al., 2018). Prostatic fine-needle aspiration is useful for the diagnosis of PN (Lévy
17 et al., 2014): usually neoplastic prostatic cells are large pleomorphic cells with some characteristics
18 as large vesicular multiple nuclei, multiple prominent nucleoli, eosinophilic intracytoplasmic
19 inclusions or vacuolizations. Cellularity is usually abundant, with single cells rarely organized in
20 clusters and dirty smear background with cellular debris or red blood cells (Leeds, 1969).
21 Radiographic findings in dogs with PN can include prostatomegaly, focal mineralization
22 (representing calcification of the gland parenchyma), irregular and poorly defined gland outlines,
23 colon's dorsal displacement and evidence of metastasis to the lungs and skeleton (Smith, 2008; Leroy
24 and Northrup, 2009; Lévy et al., 2014). If the urethra is involved in the neoplastic process, retrograde
25 cystourethrography can show mural discontinuity or compression. TC, MRI and scintigraphy are also
26 very informative but are rarely performed because of the cost, poor prognosis and lack of efficient

1 treatment (Leroy and Northrup, 2009; Lévy et al., 2014).

2 Usually the treatment is not curative and PN is associated with poor prognosis. Castration does not
3 affect the prognosis because neoplasia does not respond to the hormonal ablation strategies used in
4 humans and cytotoxic drugs do not allow to improve the prognosis. Results of radiation therapy for
5 prostate carcinoma have been disappointing and severe adverse effects have developed, so it seems
6 effective only to palliate clinical signs associated with the tumor and to relieve pain associated with
7 skeletal metastasis (Leroy and Northrup, 2009). The use of chemotherapeutic agents is still under
8 evaluation, but it appears that the anti-cancer effect of non-steroidal anti-inflammatory drugs increase
9 the survival times of dogs with prostate carcinoma (Sorenmo et al., 2004). However, because of a
10 high rate of metastasis at the time of patient presentation, the prognosis is too poor to recommend
11 aggressive local therapies; therefore, total prostatectomy is recommended only in few cases where
12 metastasis are not detected (Leroy and Northrup, 2009). Dogs that undergo complete excision of the
13 prostate are at risk of becoming incontinent while other possible complications are colonic necrosis
14 and urinary tract infection (Axiak and Bigio, 2012). The technique for total prostatectomy can be
15 described in some steps. A urethral catheter is placed to aid identification of the prostatic urethra
16 during the surgery. After laparotomy the periprostatic fat is carefully removed from prostatic ventral
17 surface to improve visualization of the prostate. The prostatic vascular supplies are identified in the
18 dorsolateral aspect of the gland. All blood vessels are ligated and the vasa deferentia as well. The
19 urinary catheter is pulled back and the urethra is transacted at the caudal and cranial margins of the
20 prostate. The prostate is removed and the catheter is reinserted in the urinary bladder to facilitate
21 approximation of the urethra. An end-to-end anastomosis of the bladder neck to the membranous
22 urethra is performed using simple interrupted sutures of 4/0 monofilament absorbable material.

24 CONCLUSIONS

25 Prostatic diseases are not as infrequent as believed, since many dogs seem to be asymptomatic. Every
26 dog, in particular from 6 years of age (Smith, 2008), may be affected and, in stud dogs, a pathological

condition of this gland can also lead to a worsening of sperm's quality and animal's fertility (Polisca et al., 2016).

Make a diagnosis is not always easy due to the non-specific clinical signs and the possible overlap of different pathologies.

In order to obtain a correct diagnosis, it is necessary to perform an accurate clinical examination and an ultrasound evaluation, the last of which is, to date, the most accurate and least invasive survey available to us. The bacteriological examination of prostate fluids and urine, the cytology of the prostate and/or its fluids and the blood test are also useful, even if a definitive diagnosis can only be obtained by histological examination.

Transrectal palpation of the organ during general medical examination and andrological check-up is important. In addition to this, the evaluation of serum CPSE can be performed because it seems to be very useful in clinical practice not only as a screening test for the prevention of BHP, but also as a test to evaluate the effectiveness of a possible set therapy. Instead, we need further studies in order to identify a prostate tumor marker, which would represent an interesting development for the early diagnosis of the disease.

Regarding the therapy, several protocols have been proposed, even recently, especially for the most widespread conditions (BHP and prostatitis), not neglecting, when possible, the preservation of the treated subjects' reproductive performances. The best results in course of BHP seem to be obtained with the use of 5 α -reductase inhibitors, antiandrogens or GnRH analogs associated, in case of concomitant prostatitis, to a targeted antibiotic therapy.

Also when a surgical approach for the treatment of the prostatic cavitory lesions (cysts and abscesses) is needed, the reproductive aspect is increasingly taken into consideration and, therefore, techniques such as omentalization (White and Williams, 1995; Zambelli and Bralia, 2000) are proposed or modified while castration is performed always in less cases and mainly only when necessary.

Conflict of interest: None of the authors has conflict of interest to declare.

REFERENCES

1. Alonge, S., Melandro, M., Leoci, R., Audi, G. (2017). Assessment of the threshold value of the Canine Prostate Specific Esterase (CPSE) to early detect dogs with ultrasonographic prostatic abnormalities. Oral exposition in International Congress EVSSAR 2017, Vienna 29 June – 1 July.
2. Atalan, G., Barr, F. J., Holt, P. E. (1999). Comparison of ultrasonographic and radiographic measurements of canine prostate dimensions. *Veterinary Radiology & Ultrasound* ,40, 408-412. Doi: 10.1111/j.1740-8261.1999.tb02133.x.
3. Axiak, S. M. & Bigio, A. (2012). Canine prostatic carcinoma. *Oncology*, 34.
4. Ballotta, G. and Cunto, M. (2018). Approccio clinico alle patologie prostatiche nel cane: quali sono e come fare diagnosi. *Veterinaria*, Year 32, n.2, April 2018, 73-82.
5. Barsanti, J. A. & Finco, D. R. (1986). Canine prostatic diseases. *Veterinary Clinics of North America: Small Animal Practice*, 16, 587-599. Doi: 10.1016/S0195-5616(86)50063-2.
6. Bell, F.W., Klausner J.S., Hayden, D.W., et al. (1991). Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). *Journal of American Veterinary Medicine Association*, 199, 1623-1639
7. Bigliardi, E., Ferrari, L. (2011). Contrast-enhanced ultrasound of the normal canine prostate gland. *Veterinary Radiology & Ultrasound*, 52 (1): 107-110.
8. Bokemeyer, J., Peppler, C., Thiel, C., Failing, K., Kramer, M., Gerwing, M. (2011). Prostatic cavitary lesions containing urine in dogs. *Journal of Small Animal Practice*; 52, 132-138.

9. Branam, J.E., Keen, C.L., Ling, G.V., Franti, C.E. (1984). Selected physical and chemical characteristics of prostatic fluid collected by ejaculation from healthy dogs and from dogs with bacterial prostatitis, *American Journal of Veterinary Research*, 45, 825-829.
10. Brendler, C. B., Berry, S. J., Ewing, L. L., McCullough, A. R., Cochran, R. C., Strandberg, J. D., Zirkin, B.R., Coffey, D.S., Wheaton, L.G., Hiler, M.L., Niswender, G.D., Scott, W.W., Bordy M. J., Walsh, P.C. (1983). Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. *Journal of Clinical Investigation*, 71, 1114. Doi: 10.1172/JCI110861.
11. Bryan, J. N., Keeler, M. R., Henry, C. J., Bryan, M. E., Hahn A. W., Caldwell, C. W. (2007). A population study of neutering status as a risk factor for canine prostate cancer. *Prostate*, 67, 1174-1181. Doi: 10.1002/pros.20590.
12. Chapdelaine, P., Dubé, J.Y., Frenette, G., Tremblay, R.R. (1984). Identification of Arginine Esterase as the Major Androgen-dependent Protein Secreted by Dog Prostate and Preliminary Molecular Characterization in Seminal Plasma. *Journal of Andrology*, 5, 206-210. Doi: 10.1002/j.1939-4640.1984.tb02395.x.
13. Cornell, K. K., Bostwick, D. G., Cooley, D. M., Hall, G., Harvey, H. J., Hendrick, M. J., Pauli, B. U., Render, J. A., Stoica, G., Sweet, D. C., Waters D. J. (2000). Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. *Prostate* 45, 173-183. Doi: 10.1002/1097-0045(20001001)45:2<173::AID-PROS12>3.0.CO;2-R.
14. Corrada, Y., Arias, D., Rodriguez, R., Spaini, E., Fava, F., Gobello, C. (2004). Effect of tamoxifen citrate on reproductive parameters of male dogs. *Theriogenology*, 61, 1327-1341.

15. Das, M. R., Patra, R. C., Das, R. K., Rath, P. K., Mishra, B. P. (2017). Hemato-biochemical alterations and urinalysis in dogs suffering from benign prostatic hyperplasia. *Veterinary World*, 10, 331. Doi: 10.14202/vetworld.2017.331-335.
16. Davidson, A.P. (2014). Prostatic Disease. *Clinician's Brief*, 81, 5.
17. Domosławska, A., Zduńczyk, S., Jurczak, A., Janowski, T. (2018). Elastography as a diagnostic tool in the prostate tumour detection in Labrador retriever. *Andrologia*, 50(10): e13139. Doi: 10.1111/and.13139.
18. Evans, H. E., De Lahunta, A. (2013). The urogenital system. *Miller's Anatomy of the Dog*, 4th ed., Elsevier Health Sciences, St. Louis, Missouri, USA, 364-365.
19. Feeney, D. A., Johnston, G. R., Klausner, J. S., Perman, V., Leininger, J. R., Tomlinson, M. J. (1987). Canine prostatic disease-comparison of radiographic appearance with morphologic and microbiologic findings: 30 cases (1981-1985). *Journal of the American Veterinary Medical Association*, 190, 1018-1026.
20. Feliciano, M. A., Maronezi, M. C., Simões, A. P., Uscategui, R. R., Maciel, G. S., Carvalho, C. F., Canola, J. C., Vicente, W. R. (2015). Acoustic radiation force impulse elastography of prostate and testes of healthy dogs: preliminary results. *The Journal of Small Animal Practice*, 56(5): 320-4. Doi: 10.1111/jsap.12323.
21. Frick, J. and Aulitzky, W.,. (1991). Physiology of the prostate, *Infection*, 19, 115-118.
22. Gobello, C., Corrada, Y. (2002). Le patologie prostatiche di origine non infettiva nel cane. *Veterinaria*, 16, 37-43.
23. Greer, M. L. (2014). Infertility and reproductive problems in the valuable stud dog-Disorder of the prostate. *Canine Reproduction and Neonatology*, Teton NewMedia CRC Press, Jackson, USA, 294-301.

24. Günzel-Apel, A. R., Möhrke, C., Poulsen Nautrup, C. (2001). Colour-coded and pulsed Doppler sonography of the canine testis, epididymis and prostate gland: physiological and pathological findings. *Reproduction in Domestic Animals*, 36 (5): 236-40.
25. Hall, W. C., Nielsen, S. W., McEntee, K. (1976). Tumours of the prostate and penis. *Bull World Health Organ*, 53, 247-256.
26. Holst, B.S., Holmroos, E., Friling, L., Hanås, S., Langborg, L.M., Franko, M.A., Hansson, K. (2017). The association between the serum concentration of canine prostate specific esterase (CPSE) and the size of the canine prostate. *Theriogenology*, 93,33-39. Doi: 10.1016/j.theriogenology.2017.01.032.
27. Iguer-Ouada, M., Verstegen, J. P. (1997). Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs. *Journal of Reproduction and Fertility Supplement*, 51, 139–149.
28. Johnston, S.D., Kamolpatana, K., Root-Kustritz, M.V., Johnston, G.R. (2000). Prostatic disorders in the dog. *Animal Reproduction Science*, 60, 405-415. Doi:10.1016/S0378-4320(00)00101-9.
29. Krawiec, D.R., Heflin, D. (1992). Study of prostatic disease in dog: 177 cases (1981-1986). *Journal of American Veterinary Medicine Association*, 200, 1119-1122
30. Lange, K., Cordes, E. K., Hoppen, H. O., Günzel-Apel, A. R. (2001). Determination of concentrations of sex steroids in blood plasma and semen of male dogs treated with delmadinone acetate or finasteride. *Journal of Reproduction and Fertility Supplement*, 57, 83-91.
31. Leeds, E.B., Leav, I. (1969). Perineal punch biopsy of the canine prostate gland. *Journal of American Veterinary Medicine Association*, 154, 925-934

32. Leoci, R., Aiudi, G., Silvestre, F., Lissner, E., Lacalandra, G. M. (2014). Effect of Pulsed Electromagnetic Field Therapy on Prostate Volume and Vascularity in the Treatment of Benign Prostatic Hyperplasia: A Pilot Study in a Canine Model. *The Prostate*, 74: 1132-1141. DOI 10.1002/pros.22829
33. Leroy, B. E., Northrup, N. (2009). Prostate cancer in dogs: comparative and clinical aspects. *Vet J* 180, 149-162. Doi: 10.1016/j.tvjl.2008.07.012.
34. Lévy, X., Mimouni, P. (2009). Hyperplasie bénigne de la prostate: actualités. *Point vétérinaire*, 40, 39-43.
35. Lévy, X., Nizański, W., Heimendahl, A., Mimouni, P. (2014). Diagnosis of common prostatic conditions in dogs: an update. *Reproduction in domestic animals*, 49, 50-57. Doi: 10.1111/rda.12296.
36. Lévy, X., Mimouni, P., Loukeri, S., Claret, E. (2017). Canine Prostate Specific Esterase as a diagnostic marker for BPH: validation study of the in-clinic test, Speed CPSE™. Oral exposition in International Congress EVSSAR 2017, Vienna 29 June – 1 July.
37. Lipowitz AJ, Schwartz A, Wilson GP, Ebert JW (1973). Testicular neoplasms and concomitant clinical changes in the dog. *Journal of American Veterinary Medicine Association*, 163, 1364-8
38. Lopate, C. (2013). Approccio clinico alle patologie del maschio. *Riproduzione e neonatologia del cane e del gatto*, 2da ed., Edizioni Veterinarie, Torino, 202-206.
39. McVary, K.T., Roehrborn, C.G., Avins, A.L., Barry, M.J., Bruskewitz, R.C., Donnell, R.F., Foster, H.F. Jr, Gonzalez, C.M., Kaplan, S.A., Penson, D.F., Ulchaker, J.C., Wei, J.T. (2011). Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. *The Journal of Urology*, 185 (5), 1793-1803.

40. Nizanski, W., Levy, X., Ochota, M., Pasikowska, J. (2014). Pharmacological treatment for common prostatic conditions in dogs benign prostatic hyperplasia and prostatitis: an update. *Reproduction in domestic animals*, 49 (2), 8-15. Doi: 10.1111/rda.12297
41. Nyland, T.G., Mattoon, J.S. (2015). Prostate and Testis. *Small Animal Diagnostic Ultrasound*, 3rd ed., Elsevier Health Sciences, St. Louis, Missouri, USA, 608-633.
42. O'Shea, J. D. (1962). Studies on the canine prostate gland: factors influencing its size and weight. *Journal of Comparative Pathology and Therapeutics*, 72, 321-331. Doi: 10.1016/S0368-1742(62)80037-X
43. Odenthal, K. P. (1996). Phytotherapy of benign prostatic hyperplasia (BPH) with Cucurbita, Hypoxis, Pygeum, Urtica and Sabal serrulata (*Serenoa repens*). *Phytother*, 10, S141–S143.
44. Pinheiro, D., Machado, J., Viegas, C., Baptista, C., Bastos, E., Magalhães, J., Pires, M.A., Cardoso, L., Martins-Bessa, A. (2017). Evaluation of biomarker canine-prostate specific arginine esterase (CPSE) for the diagnosis of benign prostatic hyperplasia. *BMC veterinary research*, 13, 76. Doi: 10.1186/s12917-017-0996-5.
45. Polisca, A., Troisi, A., Fontaine, E., Menchetti, L., Fontbonne, A. (2016). A retrospective study of canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France. *Theriogenology*, 85, 835-840. Doi: 10.1016/j.theriogenology.2015.10.030.
46. Read, R. A., Bryden, S. (1995). Urethral bleeding as a presenting sign of benign prostatic hyperplasia in the dog: a retrospective study (1979-1993). *Journal of the American Animal Hospital Association* 31, 261-267. Doi: 10.5326/15473317-31-3-261.
47. Shimizu M, Tsutsui T, Kawakami E, et al. (1995). Effect of chlormadinone acetate pellet implantation on the volume of prostate, peripheral blood levels of sex hormones and semen quality in the dog. *Journal of Veterinary Medical Science*, 57, 395-399.

48. Sirinarumitr, K., Johnston, S. D., Kustritz, M. V. R., Johnston, G. R., Sarkar, D. K., Memon, M. A. (2001). Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. *Journal of the American Veterinary Medical Association*, 218, 1275-1280.
49. Sirinarumitr, K. (2009). Medical treatment of benign prostatic hypertrophy and prostatitis in dogs. *Kirk's current veterinary therapy XIV*, J. D. Bonagura, Philadelphia, WB Saunders: 1046-1048.
50. Smith, J. (2008). Canine prostatic disease: a review of anatomy, pathology, diagnosis, and treatment. *Theriogenology*, 70, 375-383. Doi: 10.1016/j.theriogenology.2008.04.039.
51. Sorenmo, K. U., Goldschmidt, M. H., Shofer, F. S., Goldkamp, C., & Ferracone, J. (2004). Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. *Veterinary and Comparative Oncology*, 2, 13-23. Doi: 10.1111/j.1476-5810.2004.00035.x.
52. Teske, E., Naan, E. C., van Dijk, E. M., Van Garderen, E., Schalken, J. A. (2002). Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. *Mol Cell Endocrinol* 197, 251-255. Doi: 10.1016/S0303-7207(02)00261-7.
53. Trigg, T.E., Wright, P.J., Armour, A.F, Williamson, P.E., Junaidi, A., Martin, G.B., Doyle, A.G., Walsh, J. (2001). Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domestic dogs. *Journal of Reproduction and Fertility Supplement*; 57:255-261.
54. Tsutsui, T., Hori, T., Shimizu, M., Tatsuzawa, C., Kawakami, E. (2001). Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen

quality in dogs with benign prostatic hypertrophy. *Journal of Veterinary Medicine Science*; 64, 453-456.

55. Vignoli, M., Russo, M., Catone, G., Rossi, F., Attanasi, G., Terragni, R., Saunders, J., England, G. (2011). Assessment of vascular perfusion kinetics using contrast-enhanced ultrasound for the diagnosis of prostatic disease in dogs. *Reproduction in Domestic Animals*, 46(2): 209-13. Doi: 10.1111/j.1439-0531.2010.01629.x.

56. Wallace, M.S. (2001). Diagnosis and Medical Management of Canine prostatic disease. In *Atlantic Coast Veterinary Conference*. USA

57. White, R.A.S., Williams, J.M. (1995). Intracapsular prostatic omentalization: a new technique for management of prostatic abscesses in dog. *Veterinary Surgery*, 24, 390-395. Doi: 10.1111/j.1532-950X.1995.tb01349.x

58. Wolf, K., Kayacelebi, H., Urhausen, C., Piechotta, M., Mischke, R., Kramer, S., Einspanier, A., Oei, C. H. I, Günzel-Apel, A. (2012). Testicular steroids, prolactin, relaxin and prostate gland markers in peripheral blood and seminal plasma of normal dogs and dogs with prostatic hyperplasia. *Reproduction in Domestic Animals*, 47, 243-246. Doi: 10.1111/rda.12083.

59. Zambelli, D., Bralia, S. (2000). Omentalizzazione: tecnica modificata per il recupero delle performance riproduttive nel cane affetto da ascesso prostatico. *Veterinaria*, 14, 1, 31-36.

60. Zambelli, D., Cunto, M., Billi, M. G., Castagnetti C., Belluzzi S. (2003). Alcoholization in the therapy of prostatic cysts and abscess in the dog. *Proceedings of the I Congress Società Italiana di Riproduzione Animale (S.I.R.A.)*, Vico Equense, 8-10 April 2003, 37-40.

61. Zambelli, D., Cunto, M., Gentilini, F. (2012). Validation of a Model to Develop a Symptom Index for Benign Prostatic Hyperplasia in Dogs. *Reproduction in Domestic Animals*, 47, 229-231. Doi: 10.1111/rda.12084

62. Zelli, R., Orlandi, R., Troisi, A., Cardinali, L., Polisca, A. (2013). Power and pulsed Doppler evaluation of prostatic artery blood flow in normal and benign prostatic hyperplasia-affected dogs. *Reproduction in Domestic Animals*, 48(5): 768-73. doi: 10.1111/rda.12159.